ArticleCirculation research2013

An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.

Marc S Penn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.